| 1 | 1 | | 1.1 A bill for an act |
|---|
| 2 | 2 | | 1.2 relating to health insurance; requiring coverage of vasectomies by health plans; |
|---|
| 3 | 3 | | 1.3 amending Minnesota Statutes 2024, section 62Q.522, subdivision 1. |
|---|
| 4 | 4 | | 1.4BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA: |
|---|
| 5 | 5 | | 1.5 Section 1. Minnesota Statutes 2024, section 62Q.522, subdivision 1, is amended to read: |
|---|
| 6 | 6 | | 1.6 Subdivision 1.Definitions.(a) The definitions in this subdivision apply to this section. |
|---|
| 7 | 7 | | 1.7 (b) "Contraceptive method" means a drug, device, or other product approved by the |
|---|
| 8 | 8 | | 1.8Food and Drug Administration to prevent unintended pregnancy. |
|---|
| 9 | 9 | | 1.9 (c) "Contraceptive service" means consultation, examination, procedures, and medical |
|---|
| 10 | 10 | | 1.10services related to the prevention of unintended pregnancy, excluding vasectomies. This |
|---|
| 11 | 11 | | 1.11includes but is not limited to voluntary sterilization procedures, patient education, counseling |
|---|
| 12 | 12 | | 1.12on contraceptives, and follow-up services related to contraceptive methods or services, |
|---|
| 13 | 13 | | 1.13management of side effects, counseling for continued adherence, and device insertion or |
|---|
| 14 | 14 | | 1.14removal. |
|---|
| 15 | 15 | | 1.15 (d) "Medical necessity" includes but is not limited to considerations such as severity of |
|---|
| 16 | 16 | | 1.16side effects, difference in permanence and reversibility of a contraceptive method or service, |
|---|
| 17 | 17 | | 1.17and ability to adhere to the appropriate use of the contraceptive method or service, as |
|---|
| 18 | 18 | | 1.18determined by the attending provider. |
|---|
| 19 | 19 | | 1.19 (e) "Therapeutic equivalent version" means a drug, device, or product that can be expected |
|---|
| 20 | 20 | | 1.20to have the same clinical effect and safety profile when administered to a patient under the |
|---|
| 21 | 21 | | 1.21conditions specified in the labeling, and that: |
|---|
| 22 | 22 | | 1.22 (1) is approved as safe and effective; |
|---|
| 23 | 23 | | 1Section 1. |
|---|
| 24 | 24 | | REVISOR RSI/NS 25-0134512/19/24 |
|---|
| 25 | 25 | | State of Minnesota |
|---|
| 26 | 26 | | This Document can be made available |
|---|
| 27 | 27 | | in alternative formats upon request |
|---|
| 28 | 28 | | HOUSE OF REPRESENTATIVES |
|---|
| 29 | 29 | | H. F. No. 774 |
|---|
| 30 | 30 | | NINETY-FOURTH SESSION |
|---|
| 31 | 31 | | Authored by Hemmingsen-Jaeger and Feist02/13/2025 |
|---|
| 32 | 32 | | The bill was read for the first time and referred to the Committee on Commerce Finance and Policy 2.1 (2) is a pharmaceutical equivalent: (i) containing identical amounts of the same active |
|---|
| 33 | 33 | | 2.2drug ingredient in the same dosage form and route of administration; and (ii) meeting |
|---|
| 34 | 34 | | 2.3compendial or other applicable standards of strength, quality, purity, and identity; |
|---|
| 35 | 35 | | 2.4 (3) is bioequivalent in that: |
|---|
| 36 | 36 | | 2.5 (i) the drug, device, or product does not present a known or potential bioequivalence |
|---|
| 37 | 37 | | 2.6problem and meets an acceptable in vitro standard; or |
|---|
| 38 | 38 | | 2.7 (ii) if the drug, device, or product does present a known or potential bioequivalence |
|---|
| 39 | 39 | | 2.8problem, it is shown to meet an appropriate bioequivalence standard; |
|---|
| 40 | 40 | | 2.9 (4) is adequately labeled; and |
|---|
| 41 | 41 | | 2.10 (5) is manufactured in compliance with current manufacturing practice regulations. |
|---|
| 42 | 42 | | 2.11 EFFECTIVE DATE.This section is effective January 1, 2026, and applies to health |
|---|
| 43 | 43 | | 2.12plans offered, issued, or renewed on or after that date. |
|---|
| 44 | 44 | | 2Section 1. |
|---|
| 45 | 45 | | REVISOR RSI/NS 25-0134512/19/24 |
|---|